Skip to main content

Table 1 Selected parameters during rGH therapy

From: A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment

  Age [years] Height SDS Bone age [G&P] [years] Height velocity [cm/year] Predicted adult height based on Bayley-Pinneau method [cm] rGH Dose [mg/kg/24 h]
the beginning of rGH therapy 12 −3.5 10 8.5 161.9 0.024
after 6 months of rGH therapy 12 6/12 −2.9 11 10.5 164.6 0.024
after 12 months of rGH therapy 13 −2.6 13 7.5 161.7 0.024
after 2 years of rGH therapy 14 3/12 −2.2 13 6/12 10.0 168.5 0.022
after 3 years of rGH therapy 15 2/12 −2.3 14 6/12 4.5 168.5 0.018
after 4 years of rGH therapy 16 −2.3 15 2.5 166.5 0.018
after 5 years of rGH therapy 17 −2.6 16 1.3 166 Discontinuation of treatment